FDA Approval Alert: The Need-to-Know | Selumetinib in Pediatric NF1-PNs

In September 2025, the FDA approved selumetinib granules and capsules for the treatment of pediatric patients who are 1 or older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.

FDA Approves Selumetinib in Pediatric Neurofibromatosis Type 1
FDA Approves Selumetinib in Pediatric Neurofibromatosis Type 1
Article
Sep 10, 2025 2:07 PM
The FDA approved selumetinib as treatment for pediatric neurofibromatosis type 1, expanding options for young patients with inoperable plexiform neurofibromas.